| dbo:abstract |
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company. (en) Le BL-1020 (4-aminobutanoate de perphenazine) est un antipsychotique. Il s'agit d'un ester de la perphénazine et du GABA, présentant moins d'effet indésirables que cette dernière ainsi que des effets pro-cognitifs dans les essais. Il a été développé par , une société pharmaceutique israélienne. (fr) |
| dbo:casNumber |
751477-01-7 |
| dbo:chEMBL |
1187646 |
| dbo:fdaUniiCode |
K1WO7H97QZ |
| dbo:pubchem |
11203271 |
| dbo:thumbnail |
wiki-commons:Special:FilePath/Perphenazine_gamma-aminobutyrate.svg?width=300 |
| dbo:wikiPageID |
38584956 (xsd:integer) |
| dbo:wikiPageLength |
2478 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID |
1120071972 (xsd:integer) |
| dbo:wikiPageWikiLink |
dbr:Schizophrenia dbr:BioLineRx dbr:Perphenazine dbc:Chloroarenes dbc:Piperazines dbr:GABA dbr:Antipsychotic dbc:5-HT2A_antagonists dbc:Antipsychotics dbc:D2_antagonists dbc:GABA_receptor_agonists |
| dbp:c |
25 (xsd:integer) |
| dbp:casNumber |
751477 (xsd:integer) |
| dbp:chembl |
1187646 (xsd:integer) |
| dbp:chemspiderid |
9378339 (xsd:integer) |
| dbp:cl |
1 (xsd:integer) |
| dbp:h |
33 (xsd:integer) |
| dbp:iupacName |
2 (xsd:integer) |
| dbp:n |
4 (xsd:integer) |
| dbp:o |
2 (xsd:integer) |
| dbp:pubchem |
11203271 (xsd:integer) |
| dbp:s |
1 (xsd:integer) |
| dbp:smiles |
C1CNCCOCCCCN (en) |
| dbp:stdinchi |
1 (xsd:integer) |
| dbp:stdinchikey |
BABFYCSPNDKXRI-UHFFFAOYSA-N (en) |
| dbp:unii |
K1WO7H97QZ (en) |
| dbp:width |
250 (xsd:integer) |
| dbp:wikiPageUsesTemplate |
dbt:Antipsychotics dbt:Dopaminergics dbt:Drugbox dbt:GABAergics dbt:Nervous-system-drug-stub dbt:Reflist dbt:Serotonergics dbt:Short_description dbt:Fdacite |
| dcterms:subject |
dbc:Chloroarenes dbc:Piperazines dbc:5-HT2A_antagonists dbc:Antipsychotics dbc:D2_antagonists dbc:GABA_receptor_agonists |
| rdf:type |
owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 yago:WikicatAntipsychotics yago:Agent114778436 yago:CausalAgent100007347 yago:Drug103247620 yago:DrugOfAbuse103248958 yago:MajorTranquilizer103713736 yago:Matter100020827 yago:Medicine103740161 yago:PhysicalEntity100001930 yago:PsychotropicAgent104017429 dbo:Drug yago:Sedative-hypnotic104166841 yago:Sedative104166553 yago:Substance100020090 yago:Tranquilizer104470232 |
| rdfs:comment |
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials. In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company. (en) Le BL-1020 (4-aminobutanoate de perphenazine) est un antipsychotique. Il s'agit d'un ester de la perphénazine et du GABA, présentant moins d'effet indésirables que cette dernière ainsi que des effets pro-cognitifs dans les essais. Il a été développé par , une société pharmaceutique israélienne. (fr) |
| rdfs:label |
BL-1020 (en) BL 1020 (fr) |
| owl:sameAs |
freebase:BL-1020 yago-res:BL-1020 wikidata:BL-1020 dbpedia-fr:BL-1020 https://global.dbpedia.org/id/2Yof1 |
| prov:wasDerivedFrom |
wikipedia-en:BL-1020?oldid=1120071972&ns=0 |
| foaf:depiction |
wiki-commons:Special:FilePath/Perphenazine_gamma-aminobutyrate.svg |
| foaf:isPrimaryTopicOf |
wikipedia-en:BL-1020 |
| is dbo:wikiPageRedirects of |
dbr:C25H33ClN4O2S |
| is dbo:wikiPageWikiLink of |
dbr:List_of_antipsychotics dbr:BioLineRx dbr:C25H33ClN4O2S |
| is foaf:primaryTopic of |
wikipedia-en:BL-1020 |
